Trials / Completed
CompletedNCT00171171
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
A Study of Efficacy and Safety of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 252 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
Because patients with beta-thalassemia are unable to actively eliminate iron from the body, toxic and eventually lethal levels of iron can accumulate as a result of repeated blood transfusions. This study will evaluate the efficacy, safety and tolerability of deferasirox.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | deferasirox |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2006-11-01
- First posted
- 2005-09-15
- Last updated
- 2017-03-01
Locations
5 sites across 5 countries: Egypt, Lebanon, Oman, Saudi Arabia, Syria
Source: ClinicalTrials.gov record NCT00171171. Inclusion in this directory is not an endorsement.